Etcembly
Etcembly is an AI-driven drug discovery company focused on pioneering novel immunotherapies, particularly TCR and antibody design. Their core technology, EMLy™, is a repertoire decoding platform powered by protein-specific Large Language Models (LLMs) and generative AI. EMLy™ aims to accelerate drug discovery by enabling rapid design, optimization, and validation of therapeutic candidates such as TCRs, Antibodies, Bispecifics, and VHHs. The company leverages deep sequencing and proprietary databases, including data from their Long-term Cancer Survivor Study, to identify novel targets and develop more precise, safer drug candidates faster. Their mission is to combine machine and human intelligence to develop better immunotherapies for cancer patients. Etcembly has demonstrated capabilities in affinity optimization, stability improvement, and has programs like ETC-101 and ETC-201 in oncology.
Etcembly
Etcembly is an AI-driven drug discovery company focused on pioneering novel immunotherapies, particularly TCR and antibody design. Their core technology, EMLy™, is a repertoire decoding platform powered by protein-specific Large Language Models (LLMs) and generative AI. EMLy™ aims to accelerate drug discovery by enabling rapid design, optimization, and validation of therapeutic candidates such as TCRs, Antibodies, Bispecifics, and VHHs. The company leverages deep sequencing and proprietary databases, including data from their Long-term Cancer Survivor Study, to identify novel targets and develop more precise, safer drug candidates faster. Their mission is to combine machine and human intelligence to develop better immunotherapies for cancer patients. Etcembly has demonstrated capabilities in affinity optimization, stability improvement, and has programs like ETC-101 and ETC-201 in oncology.
TL;DR
Founded: 2020
Headquarters: Oxfordshire, UK
Core product: EMLy™ — AI platform for TCR and antibody discovery/engineering
Notable programme: ETC-101 — AI-designed bispecific T cell engager (reported picomolar affinity)
Team size (reported): 33 employees
Company Overview
Problem Domain
AI-driven biologics discovery and engineering focused on TCR and antibody therapeutics for oncology.
Founded
2020
Industry
Biotechnology
Tech Stack
Funding Track Record
Reported as an oversubscribed private seed round (press announcement dated April 23, 2021).
Financing announced bringing Singapore VC iGlobe Partners into the investor syndicate (Dec 15, 2022).